Intra-Cellular Therapies Inc. | Mutual Funds
Mutual Funds that own Intra-Cellular Therapies Inc.
Fidelity Growth Company Fund
3,913,167
7.15%
66,783
0.18%
07/31/2018
BB Biotech AG
2,200,000
4.01%
0
1.15%
03/31/2018
Vanguard Small Cap Index Fund
1,098,585
2%
13,758
0.03%
07/31/2018
Vanguard Total Stock Market Index Fund
1,089,186
1.99%
0
0%
07/31/2018
Rhenman & Partners Fund - Healthcare Equity L/S
1,084,581
1.98%
251,427
1.69%
12/31/2017
Fidelity Series Growth Company Fund
1,072,498
1.96%
0
0.18%
07/31/2018
iShares Russell 2000 ETF
937,385
1.71%
-501
0.04%
09/06/2018
Wasatch Small Cap Growth Fund
792,780
1.45%
0
0.84%
03/31/2018
Vanguard Small Cap Value Index Fund
691,820
1.26%
8,150
0.05%
07/31/2018
iShares Nasdaq Biotechnology ETF
631,085
1.14%
-8,253
0.14%
09/06/2018
| Address |
430 East 29th Street
New York New York 10016
United States
|
|
Employees
|
- |
| Website |
http://www.intracellulartherapies.com |
| Updated |
07/08/2019 |
| Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. |
